Last reviewed 2026-04-23 · How we verify

valsartan + simvastatin

Valsartan is an angiotensin II receptor antagonist that blocks the effects of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering cholesterol levels.

Valsartan is an angiotensin II receptor antagonist that blocks the effects of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering cholesterol levels. Used for Hypertension, Hyperlipidemia.

At a glance

Mechanism of action

Valsartan works by blocking the angiotensin II receptor, which is part of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure. By blocking this receptor, valsartan causes vasodilation and reduces blood pressure. Simvastatin, on the other hand, works by inhibiting HMG-CoA reductase, a key enzyme in the cholesterol synthesis pathway. This inhibition reduces the production of cholesterol in the liver, thereby lowering cholesterol levels in the blood.

Approved indications

• Hypertension
• Hyperlipidemia

Common side effects

• Cough
• Dizziness
• Headache
• Muscle pain
• Nausea

Key clinical trials

• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
• Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin (PHASE3)
• A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects (PHASE1)
• Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia (PHASE4)
• A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia (PHASE3)
• Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
• Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects (PHASE1)
• A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.